PE20201068A1 - Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos - Google Patents

Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos

Info

Publication number
PE20201068A1
PE20201068A1 PE2020001510A PE2020001510A PE20201068A1 PE 20201068 A1 PE20201068 A1 PE 20201068A1 PE 2020001510 A PE2020001510 A PE 2020001510A PE 2020001510 A PE2020001510 A PE 2020001510A PE 20201068 A1 PE20201068 A1 PE 20201068A1
Authority
PE
Peru
Prior art keywords
heteroaryl
halogen
same
pharmaceutical use
compounds substituted
Prior art date
Application number
PE2020001510A
Other languages
English (en)
Inventor
Tomoya Miura
Shintaro Hirashima
Tomoyuki Manabe
Tetsuya Iida
Kentaro Sakurai
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PE20201068A1 publication Critical patent/PE20201068A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a un compuesto derivado de pirazol sustituido con heteroarilo de formula [X] o una sal farmaceuticamente aceptable del mismo, en donde: R1 es hidrogeno o halogeno; R2 es alquilo C1-C6 o haloalquilo C1-C6; el anillo het es: (1) piridilo sustituido con R3, o (2) pirazinilo, pirimidinilo, o piridazinilo sustituido opcionalmente con R4; R3 es ciano, halogeno o haloalquilo C1-C3; R4 es halogeno, hidroxi, entre otros. Tambien se refiere a una composicion que lo comprende. Dicho compuesto es un inhibidor del cotransportador de sodio-glucosa 1 (SGTL1), siendo util en el tratamiento de la diabetes, en especial, la diabetes de tipo 2.
PE2020001510A 2018-04-04 2019-04-03 Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos PE20201068A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018072557 2018-04-04
PCT/JP2019/014721 WO2019194207A1 (ja) 2018-04-04 2019-04-03 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
PE20201068A1 true PE20201068A1 (es) 2020-10-19

Family

ID=68100257

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001510A PE20201068A1 (es) 2018-04-04 2019-04-03 Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos

Country Status (19)

Country Link
US (3) US10988462B2 (es)
EP (1) EP3778593A4 (es)
JP (3) JP7130588B2 (es)
KR (1) KR20200139696A (es)
CN (1) CN111902408B (es)
AR (1) AR114465A1 (es)
AU (1) AU2019249560B2 (es)
BR (1) BR112020019939A2 (es)
CA (1) CA3089092A1 (es)
CL (1) CL2020002550A1 (es)
CO (1) CO2020012353A2 (es)
IL (1) IL277686B1 (es)
MX (1) MX2020010433A (es)
PE (1) PE20201068A1 (es)
PH (1) PH12020551624A1 (es)
SG (1) SG11202009179TA (es)
TW (1) TWI805727B (es)
WO (1) WO2019194207A1 (es)
ZA (1) ZA202006053B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
BR112020019939A2 (pt) * 2018-04-04 2021-01-05 Japan Tobacco, Inc. Compostos de pirazol substituídos com heteroarila e seu uso farmacêutico
MX2022002683A (es) * 2019-09-04 2022-04-07 Japan Tobacco Inc Metodo terapeutico o profilactico para diabetes usando medicamentos combinados.
MX2022002684A (es) * 2019-09-04 2022-04-07 Japan Tobacco Inc Metodo de tratamiento o prevencion de la enfermedad renal cronica.
AU2021237149A1 (en) * 2020-03-19 2022-10-06 Japan Tobacco Inc. Treatment or prevention method for chronic heart failure

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
RU2332412C2 (ru) 2003-02-07 2008-08-27 Дайити Фармасьютикал Ко., Лтд. Производные пиразола
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
WO2004110351A2 (en) 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
US7576064B2 (en) * 2003-06-20 2009-08-18 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, drug composition containing the same and production intermediate therefor
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
JP2008505905A (ja) 2004-07-07 2008-02-28 メルク　エンド　カムパニー　インコーポレーテッド ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法
KR20070089151A (ko) 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
CA2590533C (en) * 2004-11-23 2010-09-07 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
JP2008007405A (ja) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
JP4137956B2 (ja) 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
KR100970294B1 (ko) 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 복소환 화합물
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
TWI378922B (en) * 2005-10-21 2012-12-11 Mitsubishi Tanabe Pharma Corp A pyrazole compound
JP2009523748A (ja) 2006-01-18 2009-06-25 シエナ ビオテク ソシエタ ペル アチオニ α７ニコチン性アセチルコリン受容体の調節物質およびそれらの治療への使用
US20080027014A1 (en) * 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
US8022061B2 (en) * 2006-10-10 2011-09-20 Amgen Inc. N-aryl pyrazole compounds, compositions, and methods for their use
AU2007324696B2 (en) 2006-11-24 2012-10-04 Ac Immune S.A. N- (methyl) -1H- pyrazol- 3 -amine, N- (methyl) -pyridin-2-amine and N- (methyl) -thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. Alzheimer's
EP2121619A2 (en) 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
JP4994295B2 (ja) * 2007-04-20 2012-08-08 田辺三菱製薬株式会社 医薬組成物
WO2009091813A1 (en) 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
KR20110028661A (ko) 2008-07-15 2011-03-21 노파르티스 아게 Ｄｇａｔ１ 억제제로서의 헤테로아릴 유도체
KR102113960B1 (ko) 2010-03-30 2020-05-21 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
WO2011161615A1 (en) * 2010-06-24 2011-12-29 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
WO2016050921A1 (en) * 2014-10-02 2016-04-07 F. Hoffmann-La Roche Ag Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk)
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
BR112020019939A2 (pt) * 2018-04-04 2021-01-05 Japan Tobacco, Inc. Compostos de pirazol substituídos com heteroarila e seu uso farmacêutico

Also Published As

Publication number Publication date
SG11202009179TA (en) 2020-10-29
JP2024050645A (ja) 2024-04-10
KR20200139696A (ko) 2020-12-14
JP2022166280A (ja) 2022-11-01
US20220048896A1 (en) 2022-02-17
ZA202006053B (en) 2022-03-30
CO2020012353A2 (es) 2021-01-18
RU2020132318A (ru) 2022-04-29
CN111902408B (zh) 2023-11-14
AU2019249560B2 (en) 2023-10-05
TWI805727B (zh) 2023-06-21
JP2019182852A (ja) 2019-10-24
MX2020010433A (es) 2020-10-28
US10988462B2 (en) 2021-04-27
CN111902408A (zh) 2020-11-06
AR114465A1 (es) 2020-09-09
TW201942114A (zh) 2019-11-01
CL2020002550A1 (es) 2021-01-15
BR112020019939A2 (pt) 2021-01-05
IL277686B1 (en) 2024-07-01
RU2020132318A3 (es) 2022-04-29
CA3089092A1 (en) 2019-10-10
EP3778593A1 (en) 2021-02-17
IL277686A (en) 2020-11-30
US20190330193A1 (en) 2019-10-31
AU2019249560A1 (en) 2020-07-23
EP3778593A4 (en) 2021-12-22
WO2019194207A1 (ja) 2019-10-10
US20240166632A1 (en) 2024-05-23
PH12020551624A1 (en) 2021-07-12
JP7130588B2 (ja) 2022-09-05

Similar Documents

Publication Publication Date Title
PE20201068A1 (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20181094A1 (es) Derivados heterociclicos condensados sustituidos por 2-(het)arilo como pesticidas
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
AR074238A1 (es) Compuesto de n-{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4,1.0]hept-4-il]metil}-2-heteroarilamina, su uso para la preparacion de un medicamento util para el tratamiento de una enfermedad que requiere un antagonista del receptor de orexina humano y composicion farmaceutica que lo comprende
AR066882A1 (es) Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato.
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
AR070636A1 (es) Derivados de piridina, composicion farmaceutica y uso terapeutico
AR047890A1 (es) Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
UY30499A1 (es) Derivados de amina utiles como agentes anticancerigenos
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
CR20160548A (es) Nuevos Derivados de Pirazolo Pirimidina y su Uso como Inhibidores de MALT1
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
AR057855A1 (es) Derivados de pirazina y composicion farmaceutica
CO6241157A2 (es) "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9"
AR066881A1 (es) Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato.
AR061815A1 (es) Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
AR074596A1 (es) Derivados de (3-oxo) piridazin-4-ilurea
CR9267A (es) Derivados de quinazolina para el tratamiento de la tuberculosis latente
CL2008001669A1 (es) Compuestos derivados de piperidina/piperazina inhibidora de dgat-1; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de la obesidad, dislipidemia, fibrosis hepatica y diabetes tipo ii, entre otras.
GB201201744D0 (en) Novel compounds
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
PE20141691A1 (es) Compuestos con actividad nematicida
ES2567311T3 (es) 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP